Sichuan Kelun-Biotech presents promising Phase III results for sacituzumab tirumotecan in triple-negative breast cancer, with improved progression-free and overall survival compared to chemotherapy.

Sichuan Kelun-Biotech presented promising results for its TROP2-ADC, sacituzumab tirumotecan (sac-TMT), at recent oncology conferences. A Phase III study showed sac-TMT significantly improved progression-free survival (6.7 months) and overall survival in triple-negative breast cancer (TNBC) patients compared to chemotherapy. A Phase II study indicated its potential in advanced non-small-cell lung cancer when combined with an anti-PD-L1 antibody. Sac-TMT may become a new standard treatment option for these cancers.

September 29, 2024
4 Articles

Further Reading